Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field. Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented. Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting. Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.

1.
Mateo
J
,
Steuten
L
,
Aftimos
P
,
André
F
,
Davies
M
,
Garralda
E
, et al
.
Delivering precision oncology to patients with cancer
.
Nat Med
.
2022
;
28
(
4
):
658
65
.
2.
Tsimberidou
AM
,
Kahle
M
,
Vo
HH
,
Baysal
MA
,
Johnson
A
,
Meric-Bernstam
F
.
Molecular tumour boards - current and future considerations for precision oncology
.
Nat Rev Clin Oncol
.
2023
;
20
(
12
):
843
63
.
3.
Illert
AL
,
Stenzinger
A
,
Bitzer
M
,
Horak
P
,
Gaidzik
VI
,
Möller
Y
, et al
.
The German Network for Personalized Medicine to enhance patient care and translational research
.
Nat Med
.
2023
;
29
(
6
):
1298
301
.
4.
Juric
D
,
Rodon
J
,
Tabernero
J
,
Janku
F
,
Burris
HA
,
Schellens
JHM
, et al
.
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study
.
J Clin Oncol
.
2018
;
36
(
13
):
1291
9
.
5.
Jhaveri
K
,
Chang
MT
,
Juric
D
,
Saura
C
,
Gambardella
V
,
Melnyk
A
, et al
.
Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
.
Clin Cancer Res
.
2021
;
27
(
2
):
447
59
.
6.
Krop
IE
,
Jegede
OA
,
Grilley-Olson
JE
,
Lauring
JD
,
Mitchell
EP
,
Zwiebel
JA
, et al
.
Phase II study of taselisib in PIK3CA-mutated solid tumors other than breast and squamous lung cancer: results from the NCI-match ECOG-ACRIN trial (EAY131) subprotocol I
.
JCO Precis Oncol
.
2022
;
6
:
e2100424
.
7.
Liao
X
,
Lochhead
P
,
Nishihara
R
,
Morikawa
T
,
Kuchiba
A
,
Yamauchi
M
, et al
.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
.
N Engl J Med
.
2012
;
367
(
17
):
1596
606
.
8.
Kothari
N
,
Kim
R
,
Jorissen
RN
,
Desai
J
,
Tie
J
,
Wong
HL
, et al
.
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
.
Acta Oncol
.
2015
;
54
(
4
):
487
92
.
9.
Madge
JC
,
Stallmach
A
,
Kleebusch
L
,
Schlattmann
P
.
Meta-analysis of aspirin-guided therapy of colorectal cancer
.
J Cancer Res Clin Oncol
.
2022
;
148
(
6
):
1407
17
.
10.
Khatpe
AS
,
Adebayo
AK
,
Herodotou
CA
,
Kumar
B
,
Nakshatri
H
.
Nexus between PI3K/AKT and estrogen receptor signaling in breast cancer
.
Cancers
.
2021
;
13
(
3
):
369
.
11.
Jour
G
,
Wang
L
,
Middha
S
,
Zehir
A
,
Chen
W
,
Sadowska
J
, et al
.
The molecular landscape of extraskeletal osteosarcoma: a clinicopathological and molecular biomarker study
.
J Pathol Clin Res
.
2016
;
2
(
1
):
9
20
.
12.
Choy
E
,
Hornicek
F
,
MacConaill
L
,
Harmon
D
,
Tariq
Z
,
Garraway
L
, et al
.
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
.
Cancer
.
2012
;
118
(
11
):
2905
14
.
13.
Gobin
B
,
Huin
MB
,
Lamoureux
F
,
Ory
B
,
Charrier
C
,
Lanel
R
, et al
.
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
.
Int J Cancer
.
2015
;
136
(
4
):
784
96
.
14.
Martinez-Saez
O
,
Chic
N
,
Pascual
T
,
Adamo
B
,
Vidal
M
,
González-Farré
B
, et al
.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
.
Breast Cancer Res
.
2020
;
22
(
1
):
45
.
15.
Cochicho
D
,
Esteves
S
,
Rito
M
,
Silva
F
,
Martins
L
,
Montalvão
P
, et al
.
PIK3CA gene mutations in HNSCC: systematic review and correlations with HPV status and patient survival
.
Cancers
.
2022
;
14
(
5
):
1286
.
16.
Harada
K
,
Baba
Y
,
Shigaki
H
,
Ishimoto
T
,
Miyake
K
,
Kosumi
K
, et al
.
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review
.
BMC Cancer
.
2016
;
16
:
400
.
17.
Rosty
C
,
Young
JP
,
Walsh
MD
,
Clendenning
M
,
Sanderson
K
,
Walters
RJ
, et al
.
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival
.
PLoS One
.
2013
;
8
(
6
):
e65479
.
18.
Arafeh
R
,
Samuels
Y
.
PIK3CA in cancer: the past 30 years
.
Semin Cancer Biol
.
2019
;
59
:
36
49
.
19.
Patnaik
A
,
Appleman
LJ
,
Tolcher
AW
,
Papadopoulos
KP
,
Beeram
M
,
Rasco
DW
, et al
.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas
.
Ann Oncol
.
2016
;
27
(
10
):
1928
40
.
20.
Doi
T
,
Fuse
N
,
Yoshino
T
,
Kojima
T
,
Bando
H
,
Miyamoto
H
, et al
.
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
.
Cancer Chemother Pharmacol
.
2017
;
79
(
1
):
89
98
.
21.
Damodaran
S
,
Zhao
F
,
Deming
DA
,
Mitchell
EP
,
Wright
JJ
,
Gray
RJ
, et al
.
Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-match ECOG-ACRIN trial (EAY131) subprotocol Z1F
.
J Clin Oncol
.
2022
;
40
(
14
):
1552
61
.
22.
Ando
Y
,
Iwasa
S
,
Takahashi
S
,
Saka
H
,
Kakizume
T
,
Natsume
K
, et al
.
Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
.
Cancer Sci
.
2019
;
110
(
3
):
1021
31
.
23.
Piha-Paul
SA
,
Taylor
MH
,
Spitz
D
,
Schwartzberg
L
,
Beck
JT
,
Bauer
TM
, et al
.
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
.
Oncotarget
.
2019
;
10
(
60
):
6526
35
.
24.
Ando
Y
,
Inada-Inoue
M
,
Mitsuma
A
,
Yoshino
T
,
Ohtsu
A
,
Suenaga
N
, et al
.
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
.
Cancer Sci
.
2014
;
105
(
3
):
347
53
.
25.
Bendell
JC
,
Rodon
J
,
Burris
HA
,
de Jonge
M
,
Verweij
J
,
Birle
D
, et al
.
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
.
J Clin Oncol
.
2012
;
30
(
3
):
282
90
.
26.
Andre
F
,
Ciruelos
E
,
Rubovszky
G
,
Campone
M
,
Loibl
S
,
Rugo
HS
, et al
.
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
.
N Engl J Med
.
2019
;
380
(
20
):
1929
40
.
27.
Savas
P
,
Lo
LL
,
Luen
SJ
,
Blackley
EF
,
Callahan
J
,
Moodie
K
, et al
.
Alpelisib monotherapy for PI3K-altered, pretreated advanced breast cancer: a phase II study
.
Cancer Discov
.
2022
;
12
(
9
):
2058
73
.
28.
Keam
B
,
Hong
MH
,
Shin
SH
,
Heo
SG
,
Kim
JE
,
Ahn
HK
, et al
.
Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma: KCSG HN 15-16 TRIUMPH trial
.
J Clin Oncol
.
2024
;
42
(
5
):
507
17
.
29.
Subbiah
V
,
Wagner
MJ
,
McGuire
MF
,
Sarwari
NM
,
Devarajan
E
,
Lewis
VO
, et al
.
Personalized comprehensive molecular profiling of high risk osteosarcoma: implications and limitations for precision medicine
.
Oncotarget
.
2015
;
6
(
38
):
40642
54
.
30.
Moscow
JA
,
Fojo
T
,
Schilsky
RL
.
The evidence framework for precision cancer medicine
.
Nat Rev Clin Oncol
.
2018
;
15
(
3
):
183
92
.
31.
Moyers
JT
,
Subbiah
V
.
Think globally, act locally: globalizing precision oncology
.
Cancer Discov
.
2022
;
12
(
4
):
886
8
.
32.
Lotsberg
ML
,
D’mello Peters
SA
.
Publication bias in precision oncology and cancer biomarker research; challenges and possible implications
. In:
Bremer
A
,
Strand
R
, editors.
Precision oncology and cancer biomarkers: issues at stake and matters of concern
.
Cham
:
Springer International Publishing
;
2022
. p.
155
74
.
33.
Westphalen
CB
,
Quante
M
,
Söhlke
B
,
Wartenberg
M
,
Knauf
W
,
Illmer
T
, et al
.
Sektorenübergreifende interdisziplinäre Zusammenarbeit der Arbeitsgemeinschaft Internistische Onkologie in der Präzisionsonkologie
.
Onkologe
.
2022
;
28
(
S1
):
6
16
.
You do not currently have access to this content.